Related Experiment Videos
Type III and type IV hypersensitivity reactions due to mitomycin C
L Kunkeler1, C Nieboer, D P Bruynzeel
1Department of Occupational Dermatology, Free University Hospital, Amsterdam, The Netherlands.
Contact Dermatitis
|March 7, 2000
Summary
A patient experienced severe skin reactions, including eczema and purpura, during bladder cancer treatment with mitomycin C. These systemic reactions resolved after discontinuing the drug.
Area of Science:
- Dermatology
- Oncology
- Immunology
Background:
- Mitomycin C is a chemotherapy agent used intravesically for bladder cancer.
- Adverse skin reactions to chemotherapy can occur, impacting patient quality of life.
Observation:
- A 71-year-old man developed exfoliative dermatitis and generalized itching during mitomycin C treatment.
- Positive patch tests confirmed mitomycin C hypersensitivity.
- Palpable purpura on the legs emerged during repeat patch testing.
Findings:
- Histopathological and immunofluorescence studies indicated Henoch-Schonlein-type purpura.
- The patient exhibited systemic reactions including eczematous dermatitis and purpura.
- Discontinuation of mitomycin C led to complete resolution of skin issues.
Implications:
- This case highlights the potential for systemic hypersensitivity reactions to intravesical mitomycin C.
- Early identification and management of mitomycin C-induced skin reactions are crucial.
- Understanding immune-complex mechanisms is vital for managing chemotherapy-related adverse events.